Sviatlana Zyhmantovich
- Cell therapy developer Artiva Biotherapeutics (ARTV), whose collaborators include German biotech Affimed (AFMD), has filed with the SEC to raise up to $100M in an initial public offering under the ticker symbol “ARTV.”
- The San Diego, California-based biotech previously filed for a $100M IPO in 2021 to list under the ticker symbol “RTVA” and withdrew its plans in late 2022.
- Artiva (RTVA) instead signed an agreement with Affimed (AFMD) to collaborate on a drug combo involving its lead asset, AlloNK, an NK cell therapy previously known as AB-101.
- Artiva (ARTV), a cancer drug developer focused on developing “off-the-shelf” product candidates derived from donor cells (allogeneic), is currently testing AlloNK in a Phase 1/1b trial for lupus nephritis, which is set to generate data in H1 2025.